Kazia's ongoing Phase 1 clinical trial tackling brain metastases, using paxalisib in combination with radiotherapy, will be showcased at the upcoming 2022 Annual Conference on CNS (central nervous system) Clinical Trials and Brain Metastases.
The conference is jointly organised by the Society for Neuro-Oncology (SNO) and the American Society for Clinical Oncology (ASCO), and will be held in Toronto, Canada, from August 12-13. The trial is sponsored by the Memorial Sloan Kettering Cancer Center in New York.
Overall response rate of 100%
Interim data from the first stage of the study reports that all nine evaluable patients experienced complete or partial response, representing an overall response rate (ORR) of 100%.
Read more here
